- Home
- KUKE vs CRBP Comparison
KUKE vs CRBP Comparison
Compare KUKE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- CRBP
- Stock Information
- Founded
- KUKE 2002
- CRBP 2009
- Country
- KUKE China
- CRBP United States
- Employees
- KUKE N/A
- CRBP N/A
- Industry
- KUKE Other Consumer Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- CRBP Health Care
- Exchange
- KUKE Nasdaq
- CRBP Nasdaq
- Market Cap
- KUKE 86.8M
- CRBP 96.5M
- IPO Year
- KUKE 2021
- CRBP N/A
- Fundamental
- Price
- KUKE $3.07
- CRBP $7.16
- Analyst Decision
- KUKE
- CRBP Strong Buy
- Analyst Count
- KUKE 0
- CRBP 10
- Target Price
- KUKE N/A
- CRBP $53.56
- AVG Volume (30 Days)
- KUKE 8.9K
- CRBP 221.2K
- Earning Date
- KUKE 07-31-2025
- CRBP 08-05-2025
- Dividend Yield
- KUKE N/A
- CRBP N/A
- EPS Growth
- KUKE N/A
- CRBP N/A
- EPS
- KUKE N/A
- CRBP N/A
- Revenue
- KUKE $9,442,397.00
- CRBP N/A
- Revenue This Year
- KUKE N/A
- CRBP N/A
- Revenue Next Year
- KUKE N/A
- CRBP $150.03
- P/E Ratio
- KUKE N/A
- CRBP N/A
- Revenue Growth
- KUKE N/A
- CRBP N/A
- 52 Week Low
- KUKE $1.45
- CRBP $4.64
- 52 Week High
- KUKE $17.50
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- KUKE 44.73
- CRBP 40.85
- Support Level
- KUKE $2.95
- CRBP $7.66
- Resistance Level
- KUKE $3.03
- CRBP $8.71
- Average True Range (ATR)
- KUKE 0.11
- CRBP 0.54
- MACD
- KUKE 0.03
- CRBP -0.23
- Stochastic Oscillator
- KUKE 53.57
- CRBP 16.17
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.